Abstract
The spread of infectious diseases such as COVID-19 presents many challenges to healthcare systems and infrastructures across the world, exacerbating inequalities and leaving the world’s most vulnerable populations most affected. Given their density and available infrastructure, refugee and internally displaced person (IDP) settlements can be particularly susceptible to disease spread. Non-pharmaceutical public health interventions can be used to mitigate transmission, and modeling efforts can provide crucial insights on the potential effectiveness of such interventions to help inform decision making processes. In this paper we present an agent-based modeling approach to simulating the spread of disease in refugee and IDP settlements. The model, based on the JUNE open-source framework, is informed by data on geography, demographics, comorbidities, physical infrastructure and other parameters obtained from real-world observations and previous literature. Furthermore, we present a visual analytics tool which allows decision makers to distill insights by comparing the results of different simulations and scenarios. Through simulating their effects on the epidemiological development of COVID-19, we evaluate several public health interventions ranging from increasing mask wearing compliance to the reopening of learning institutions. The development and testing of this approach focuses on the Cox’s Bazar refugee settlement in Bangladesh, although our model is designed to be generalizable to other informal settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
United Nations Global Pulse work is supported by the Government of Sweden, and the William and Flora Hewlett Foundation. JAB, CCL, AQB and AS are also supported by the UKRI-STFC grant number ST/P006744/1. This work used the DiRAC@Durham facility managed by the Institute for Computational Cosmology on behalf of the STFC DiRAC HPC Facility (www.dirac.ac.uk). The equipment was funded by BEIS capital funding via STFC capital grants ST/K00042X/1, ST/P002293/1, ST/R002371/1 and ST/S002502/1, Durham University and STFC operations grant ST/R000832/1. DiRAC is part of the UK's National e-Infrastructure.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research has been designed and conducted following relevant data privacy and data protection principles and processes, including UNHCR data protection policies and guidelines, as well as the UN principles on Personal Data Protection and Privacy, and the UNSDG Guidance Note on Big Data for the 2030 Agenda: Ethics, Privacy and Data Protection. Data used for building the digital twin come from statistical data, other open datasets and anonymous and aggregated survey data used collected by UN agencies as cited throughout this document.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Main author name change and fixing minor typos
12 Note that in our model, we allow for the possibility of severe cases and death without hospitalization.
↵13 This is the setting in which the JUNE model was developed, and was therefore an already-available source of detailed COVID-19 data.
↵14 Comorbidity prevalence rates are provided for each comorbidity, and we do not have data on how often particular comorbidities coincide. Therefore, we do not know how many people have no comorbidities. To calculate this number we follow the general strategy outlined in Clark et al. [43]. First, we assume that comorbidities are independently distributed, and calculate the expected proportion of people with one or more comorbidities; we then scale this proportion by 0.9 to account for likely correlations between comorbidities. Next, we confirm that the estimated proportion of people with one or more comorbidities is greater than the proportion of people with each single comorbidity; otherwise, we set the estimated proportion of people with one or more comorbidities equal to the proportion of people with the most common comorbidity. Subtracting this number from 1, we obtain the estimated proportion of people with no comorbidities. That is,
↵15 While there are active efforts to track illness in the camps, these efforts are oriented towards communicable disease and did not provide sufficient data to estimate the prevalence of the diseases in Table 5. Therefore, we have used the population of Myanmar as the reference population for comorbidity prevalence estimates.
Data Availability
In the interest of openness and transparency, the simulation code has been released under a GPL v3 license. Given the sensitivity of this situation, more information about the datasets used and how to access them is available upon request.